Scripps Research study suggests insomnia drug could be repurposed for alcohol use disorder Orexin-receptor antagonist suvorexant (Belsomra ) reduced alcohol intake and blocked relapse in preclinical tests.
January 10, 2023
LA JOLLA, CA An insomnia drug has shown promise as a potential treatment for alcohol use disorder, in a preclinical study from Scripps Research.
The drug, suvorexant (Belsomra ), blocks the activity of brain-cell receptors called orexin receptors, which normally help regulate wakefulness, appetite and motivation, mood, energy expenditure and stress-related behaviors. In the study, published Dec. 22, 2022, in Frontiers in Behavioral Neuroscience, the drug strongly reduced voluntary alcohol intake in alcohol-dependent rats, and blocked stress-induced relapse.
These results support the idea of targeting the orexin system for the treatment of alcohol and other substance use disorders, says study senior author Remi Martin-Fardon, PhD, associate professor of Molecular Medicine at Scripps Research.
The study's first author was Francisco Flores-Ramirez, PhD, a postdoctoral research associate in the Martin-Fardon lab.
Alcohol-use disorder, which includes chronic heavy alcohol use and binge drinking, is one of the world's top public health concerns. In the United States alone, it is estimated to affect about 15 million people, killing about 100,000 annually and contributing to a host of health problems, including hypertension, heart disease, dementia and cancers. According to the World Health Organization, more than five percent of the global burden of disease and injury is attributable to alcohol. Treatments include counseling, support groups and drugs such as naltrexone, but most of the time end in relapse.
Over the past decade and a half, studies have implicated orexin signaling in alcoholism and relapse. In humans and other mammals, there are two orexin proteins, orexin-A and orexin-B, which work by binding to distinct orexin receptors on cells throughout the nervous system. Suvorexant blocks the activities of both receptors, and in 2014 became the first orexin-targeting drug to receive U.S. Food and Drug Administration approval though it was developed for treating insomnia.
In the study, Martin-Fardon's team tested suvorexant in rat models of human alcohol dependency and relapse. For the first experiment, they induced dependency by exposing the animals to alcohol vapor 14 hours a day for six weeks. They also trained the rats to self-administer sips of alcohol which the animals did, reliably and at ever-escalating doses whenever the shutoff of the vapor induced withdrawal pangs. Treatment with suvorexant, however, reduced the rats' alcohol use during withdrawal to the same low levels seen in rats that had no alcohol dependency.
Similarly, in rats modeling the stress-induced relapse of alcohol misuse, suvorexant blocked the usual binge-like resumption of alcohol-seeking behavior.
The findings represent further evidence that targeting orexin signaling could be an effective new approach for reducing alcohol misuse. Martin-Fardon notes that study co-author Barbara Mason, PhD, Pearson Family Chair of the Department of Molecular Medicine at Scripps Research, is conducting a clinical trial of the same drug in people with alcohol use disorder.
Martin-Fardon adds that suvorexant and similar insomnia drugs may inhibit alcohol misuse via multiple mechanisms, including reductions in stress, cravings, and sleep disturbances.
These individuals often cannot sleep without resorting to alcohol, so by treating them with an orexin-blocking drug at night, we help them sleep better and hopefully their improved sleep will help reduce the cravings they feel in the daytime, Martin-Fardon says.
He emphasizes that the same strategy could work for other substance use disorders, and his lab currently is studying its effects against prescription opioid dependency.
Alternative use of suvorexant (Belsomra ) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence was co-authored by Francisco Flores-Ramirez, Jessica Illenberger, Glenn Pascasio, Alessandra Matzeu, Barbara Mason, and R mi Martin-Fardon, all of Scripps Research during the study.
The research was supported by the National Institute on Alcohol Abuse and Alcoholism (AA026999, AA028549, AA006420, T32 AA007456).
Neurological Disorders Translational Medicine Martin-Fardon, Remi
Most recent headlines
06/10/2025
France T l visions, France's leading broadcaster, has received the 2025 EBU ...
04/09/2025
Monumental Sports & Entertainment (MSE), in collaboration with Dalet, has been a...
30/08/2025
WASHINGTON The Federal Communications Commission has adopted its FY 2025 Regulatory Fees Order that establishes the regulatory fee rates for the broadcast stati...
29/08/2025
Australian Red Cross and SBS launch training to help workplaces in the fight aga...
29/08/2025
The National Film and Video Foundation (NFVF), an agency of the Department of Sp...
29/08/2025
L3Harris Technologies has concentrated decades of expertise across the entire enterprise to develop affordable and reliable best-of-breed solutions to rapidly c...
29/08/2025
BURBANK, Calif. The CW Network and the Pac-12 Conference have announced a new media rights deal that will extend their broadcast partnership beginning with the ...
29/08/2025
NEW YORK Gracenote has released a new analysis of its global video dataset showing that the number of FAST channels grew nearly 14% from Q1 2025 and 76% since 2...
29/08/2025
SAN JOSE, Calif. Harmonic has announced a series of improvements to its live sports streaming solution that the company said will improve fan engagement, protec...
29/08/2025
NEW YORK and LOS ANGELES Fox Corp. and YouTube TV last night announced a renewal of the full portfolio of Fox networks, including Fox News Channel, Fox Business...
29/08/2025
Budapest, Hungary, August 2025 - The integration of Microsoft Teams Rooms (MTR) with Lightware's Taurus universal matrix switchers delivers a new level of f...
29/08/2025
Frequency, the engine behind many of the world's best-known streaming television channels, today announced it will launch Studio Live, a next-generation uni...
29/08/2025
In an era when AI and cyber resilience are essential, Scality will mark the 10th anniversary of Scality Day on October 16, 2025 in Paris. This flagship global e...
29/08/2025
Disguise's In-House Creative and Technical Teams Pre-Visualised, Programmed and Delivered Content for the Experience, All Powered by EX 3+
Technology solu...
29/08/2025
Disguise will be demonstrating the latest workflows for TV, film and live events on a number of partner booths at the show
Disguise, the industry-leading tech...
29/08/2025
STOCKHOLM, Sweden Accedo will showcase Accedo Compose, its AI agent-powered modular orchestration layer that assists streaming providers in transitioning client...
29/08/2025
LOS ANGELES Cineverse has announced that it is working with Xperi to bring four of its streaming channels to automobiles for the first time as part of the DTS A...
29/08/2025
DALLAS & ATLANTA Gray Media has announced an agreement with the sports streaming service Victory+ to simulcast 17 Dallas Stars NHL games in 15 television market...
29/08/2025
NEW YORK AND CULVER CITY Comcast NBCUniversal and Amazon have announced new and extended distribution agreements that will expand the content available on their...
29/08/2025
FOOTHILL RANCH, Calif. RED Digital Cinema will feature its Cine-Broadcast Module supporting live broadcast workflows during IBC2025, Sept. 12-15, at the RAI Ams...
29/08/2025
29 Aug 2025
Kyivstar Rings Opening Bell at Nasdaq Marking Landmark Listing and ...
29/08/2025
More than half of all NFL games live on Sky for the first timeFriday 29 August 2025
Sky Sports has announced a new three-year deal with the NFL, extending its ...
29/08/2025
Back to All News
RIV4LRIES: The Trailer of the New Series With Samuele Carrino ...
29/08/2025
Get ready for an inspiring and emotional insight into the world of competitive Irish dancing with My Story: Tomi Champion of the World airing on RT 2 this monda...
29/08/2025
RT has today announced that David McCullagh is to be the new presenter of RT Radio 1's flagship Today programme, which airs every weekday at 10am, replaci...
28/08/2025
By Kristin Feeley, Director, Documentary Film & Artist Programs
If you want to tell untold stories, if you want to give voice to the voiceless, you've got ...
28/08/2025
Directed by Steven Bognar and Julia Reichert, Sundance Institute-supported Amer...
28/08/2025
Corridos have been a cornerstone of M sica Mexicana for generations, telling stories rooted in everyday life. Now, a new chapter is taking shape: motivational c...
28/08/2025
Los corridos han sido un pilar de la M sica Mexicana durante generaciones, contando historias enraizadas en la vida cotidiana. Ahora, un nuevo cap tulo est tom...
28/08/2025
Earlier this month, we promised our Verano Forever party would bring the heat, a...
28/08/2025
L3Harris will provide the Polish F-16V fleet with the Viper Shield electronic warfare system as part of an upgrade program....
28/08/2025
Bilbao, August 26, 2025 - AgileTV, an international television and video technol...
28/08/2025
Ken Wilkinson is an Emmy Awards nominated New York audio engineer who specialises in production sound mixing for film, commercial, episodic and documentary work...
28/08/2025
NEW YORK FuboTV today announced that it will launch Fubo Sports, a skinny bundle that focuses on sports with a subscription price of $56 monthly....
28/08/2025
NEVADA City, Calif. At IBC2025, Sept. 12-15 at the RAI Amsterdam, Telestream will debut its new Global Ingest strategy, introducing a next-generation ingest arc...
28/08/2025
Dr. Rhoda Bernard Releases Groundbreaking Debut Book on Accessible Arts Educatio...
28/08/2025
TAG Video Systems, the leader in software-based IP end-to-end workflow monitoring, deep probing, and real-time visualization, has named Oliver Gappa as Sales Di...
28/08/2025
AI-based voice enhancement will be among a series of innovations making their IBC 2025 debut on the DHD stand B46 in Hall 8 at the RAI Amsterdam Convention Cent...
28/08/2025
Telef nica Servicios Audiovisuales (TSA), the leading system integrator and service provider in the media sector in Spain, with the support of Appear, the globa...
28/08/2025
To fully immerse sailing fans in the world's biggest offshore yacht race, production company, Optical Media turned to LiveU's On-site Production solutio...
28/08/2025
Working with Calrec on its most recent overhaul, radio and television broadcaster, WNED has migrated to a fully IP infrastructure with multiple Type R consoles,...
28/08/2025
Cleeng, the Subscriber Retention Management (SRM ) inventor, has unveiled Cleeng Pro, the first-ever direct-to-consumer (D2C) subscription management platform t...
28/08/2025
Zixi, the industry leader in live broadcast-quality video over IP, today announced that French media distribution platform OKAST has selected Zixi to enable rel...
28/08/2025
Solution offers a streamlined, speaker-free architecture to optimize integration with premium external loudspeakers and advanced loudness metering
Nixer Pro Au...
28/08/2025
Cinegy, the premier provider of software-defined television technology, has announced a strategic partnership with Vision One Touch Film Production Services L.L...
28/08/2025
Telestream, a global leader in media workflow technologies, will debut its new Global Ingest strategy at IBC2025, introducing a next-generation ingest architect...
28/08/2025
Tier 1 operator selects Broadpeak to power high-performance, unified CDN solution across Norway, Sweden and Finland
Broadpeak, a leader in streaming and moneti...
28/08/2025
Leading video software provider, Synamedia, today announced that 24 Frames Digital, one of India's leading live event streaming service providers, has chose...
28/08/2025
Meet VisualOn at IBC2025: See What's Next in AI-Powered Video Streaming Join VisualOn at IBC2025 and discover how our AI-driven Optimizer and advanced media...
Scripps Research study suggests insomnia drug could be repurposed for alcohol use disorder Orexin-receptor antagonist suvorexant (Belsomra ) reduced alcohol intake and blocked relapse in preclinical tests.
